Skip to main content
Premium Trial:

Request an Annual Quote

Singlera Genomics Closes $150M Series B Financing Round

NEW YORK — Singlera Genomics said on Tuesday that it has raised $150 million in a Series B financing round.

The round was led by CICC Kai Tak Innovative Biomedicine Fund and co-led by Detong Capital and Furong Investment. New investors include Huamei International, Linden Asset Group, Wuxi Capital, FutureX Skyline Capital, and Shanghai Free Trade Zone Fund. Existing investors participating in the financing include Greenpine Capital, Prosperico Ventures, and Proxima Ventures.

Singlera said it will use the new funding to expand its research and development of new early cancer screening products, to support regulatory and commercialization activities, and to expand prospective studies into pan-cancer early screening.

This summer, Singlera and collaborators at Fudan University published data showing that the company's circulating tumor DNA methylation multi-cancer screening technology, called PanSeer, could help detect cancer in asymptomatic people who were later diagnosed with cancer.

While La Jolla, California-based Singlera, which also has operations in Shanghai, is initially focusing on colorectal cancer detection with the PanSeer technology, it aims to expand to a pan-cancer setting in the future.

"We have developed early cancer screening and diagnostic technologies and products covering a variety of cancer types including lung, colorectal, liver, stomach, esophageal, pancreatic, and thyroid," Singlera Cofounder and scientific advisor Yuan Gao said in a statement. "This round of financing will help us carry out large-scale prospective studies and clinical trials."

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.